The “Luck” and “Randomness” of Index Funds
Please select the image below to download the document. Image shown, page 1 of 14. Tickerized for Valuentum’s coverage universe.
MD
Boeing!
Image shown: Boeing’s shares have been rocketing higher of late! We couldn’t be more pleased with how one of our best ideas for consideration has performed: Boeing! By Kris Rosemann Dividend Gowth Newsletter portfolio idea Boeing (BA) continues its tremendous share-price run of late, hitting all-time highs following its earnings report before market open January 31. The aerospace giant turned in 9% revenue growth on a year-over-year basis, while GAAP earnings per share doubled from the year-ago period to $5.18. Free cash flow remained robust in the full-year 2017, advancing to ~$11.6 billion from ~$7.9 billion in 2016. The company expects operating cash flow to climb to ~$15 billion in 2018 (up from $13.3 billion in 2017), and its revenue … Read more
Video: Quants! You’re NOT Measuring VALUE and Nelson’s Theory of Universal Value
President of Investment Research Brian Nelson defines the concept of universal value and shows how quantitative statistical methods are inextricably linked to those of fundamental, financial, business-model related analysis. Value does not exist in respective process vacuums! Value is universal. Find out why. Running time: ~10 minutes. Tickerized for Valuentum’s stock and ETF coverage universe. Transcript Hi this is Brian Nelson from Valuentum Securities, and this is the tenth edition of a series that I call “Off the Cuff,” where I get in front of the camera and I talk for ten minutes. This is what we have to talk about today. We have to talk about this concept: The Theory of Universal Value. Value does not exist in vacuums … Read more
Divestitures Sweeping Through the Pharmaceutical Industry
Image Source: Paul Sableman There has been a notable rise in the intent of the old guard in the pharmaceutical realm to divest some non-core assets via spin-offs into new, standalone companies. We believe we are on the cusp of a trend of simplification which we feel will aid in growing the top line sustainably, something that has become notoriously difficult for big pharma. By Alexander J. Poulos Eli Lilly Eli Lilly (LLY) mentioned on its recent quarterly conference call the need to explore strategic alternatives for its Elanco animal health unit, which is suffering from sales deceleration due to a decrease in end-user demand for its products. Elanco posted sales of $2.29 billion during the first three quarters of … Read more
Reimbursement Uncertainty Weighs on DaVita
DaVita has been left out in the cold with its share price losing ground in 2017 due to continued fears over reimbursement of care. By Alexander J. Poulos Overview DaVita (DVA) is an innovative healthcare provider with its primary focus on high-quality dialysis care. DaVita has embarked on a journey to consolidate the highly-fragmented dialysis care market through a series of acquisitions, which have transformed the enterprise into one of the largest providers in the United States. Industry consolidation is inevitable as US government insurance (Medicare) accounts for the bulk of reimbursement. We feel the industry operates as a quasi-oligopoly with few incentives for the individual players to compete on price. Reimbursement Woes We feel Davita remains under a cloud … Read more
Amazon Casts a Large Shadow Over the Pharmacy Industry
Image Source: Mike Mozart It is our belief the food retailing industry is in the midst of widespread disruption with Amazon’s attempt to break into the supermarket game with its audacious purchase of Whole Foods. The Whole Foods acquisition is not likely to be an isolated one-off event; instead, it may be a harbinger of Amazon’s ambition to break into new markets, thus expanding its overall percentage of retail sales. We update our views on Amazon and how the company may eventually impact newsletter portfolio holding CVS Health. By Alexander J. Poulos Emulating the Costco Model Amazon’s (AMZN) purchase of Whole Foods (WFM) may be the initial step towards emulating the uber-successful Costco (COST) model where the bulk of profits … Read more
Valuentum’s 3 Breakthroughs in the Field of Finance and More
Valuentum’s President Brian Nelson pauses for a picture before speaking at the CFA Society of Houston in March 2017. By Valuentum Editorial Staff Let’s cover Valuentum’s 3 major breakthroughs in the field of finance. The first one is big and may challenge you to rethink everything you think you know about investing. 1. On a logical framework, Valuentum has debunked John C. Bogle’s landmark syllogism that has paved the way for the concept of index investing. Index investing has been built on a logical shortcoming, whether supported by evidence or not. We think it is important that the investment community know of this. Read (pdf): The “Luck” and “Randomness” of Index Funds (2018), Brian Nelson, CFA See video documentation: /FALLACY_of_Index_Funds To … Read more
Is There Value in DaVita?
With healthcare the primary focus in Washington, let’s evaluate the investment case for DaVita. We discuss how potential changes can impact the economics of the dialysis market. By Alexander J Poulos The healthcare sector remains in focus with the renewed emphasis on repealing/replacing the Affordable Care Act. The uncertainty that has crept into the industry may offer an appealing entry into the industry for those currently on the sidelines. The write-up below discusses the prospects of DaVita Inc (DVA), one of the largest providers of dialysis care in the United States. The Inelastic Demand for Dialysis The dialysis market mirrors the use of insulin, the classic economics example of inelastic demand. The demand for dialysis remains unfazed irrespective of market … Read more
5 US-Centric Undervalued Stocks with Fantastic Economics
“In business, I look for economic castles protected by unbreachable moats.” – Warren Buffett << Read more about Economic Castles Image Source: Rob Faulkner The see-sawing action in the US markets has not let up, with the latest wave of the upward variety. The S&P 500 (SPY), however, remains nearly 8% off its all-time highs, as global markets continue to ebb and flow with news of negative economic data followed by the prospects of an ever-easing monetary environment and so on. Several major economies across continents are in technical recession (Brazil, Canada, etc), while others continue to face a slowing pace of economic expansion, not the least of which are Australia (EWA) and China (FXI). The global economic outlook is … Read more
Valuentum Economic Castleâ„¢ Rating Update
Read: Keeping the Horse Before the Cart: Valuentum’s Economic Castle™ Rating The Economic Castle Focuses on the Magnitude of Economic Value Creation The Valuentum Economic Castle™ rating is an enhancement of the competitive advantage framework (commonly known as economic moat analysis) that has become widespread and ubiquitous within the investing world. Whereas an economic moat framework evaluates a firm on the basis of the sustainability and durability of its competitive advantages, Valuentum’s Economic Castle™ rating evaluates a firm on the basis of the firm’s future economic profit spread (return on invested capital less its weighted average cost of capital). The companies with the strongest Valuentum Economic Castle™ ratings are poised to generate the most economic value for shareholders in the … Read more